Filtered By:
Source: Molecular Cancer
Therapy: Neoadjuvant Chemotherapy Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling
Conclusion:
We could firstly show that SFRP1 strongly correlates with the triple negative breast cancer subtype and secondly, that SFRP1 might be used as a marker stratifying patients to positively respond to neoadjuvant chemotherapy. The mechanisms by which tumor suppressor SFRP1 influences carcinogenic properties of cancer cells do not rely on Wnt signaling, thereby demonstrating the complexity of tumor associated signaling pathways.
Source: Molecular Cancer - July 17, 2014 Category: Cancer & Oncology Authors: Christof BernemannCarolin HülsewigChristian RuckertSarah SchäferLena BlümelGeorg HempelMartin GötteBurkhard GrevePeter BarthLudwig KieselCornelia Liedtke Source Type: research
